Effects of nonsteroidal anti-inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage.
Platelet function is impaired by nonsteroidal anti-inflammatory drugs (NSAIDs) with prominent anti-inflammatory properties. Their safety in patients undergoing intracranial surgery is under debate. Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH. Treatment was continued for 3 days postoperatively. Test blood samples were taken before treatment and surgery as well as on the first, third, and fifth postoperative mornings. Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen. Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day. In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05). One patient in the ketoprofen group developed a postoperative intracranial hematoma. Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups. Ketoprofen but not acetaminophen impaired platelet function in patients with SAH. If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.
Niemi
T
T
Department of Anesthesiology, Töölö Hospital, Helsinki University Central Hospital, Finland.
Tanskanen
P
P
Taxell
C
C
Juvela
S
S
Randell
T
T
Rosenberg
P
P
D000082:Acetaminophen / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D000990:Antithrombin III / Q000187:drug effects; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D005260:Female; D005340:Fibrinogen / Q000187:drug effects; D005500:Follow-Up Studies; D006406:Hematoma / Q000139:chemically induced; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D002532:Intracranial Aneurysm / Q000097:blood / Q000601:surgery*; D007660:Ketoprofen / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D012449:Safety; D013345:Subarachnoid Hemorrhage / Q000097:blood*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010975:Platelet Aggregation Inhibitors; D000082:Acetaminophen; D000244:Adenosine Diphosphate; D000990:Antithrombin III; D005340:Fibrinogen; D007660:Ketoprofen